Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c
August 9, 2022 7:17 AM EDTFoghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.66), $0.09 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $8.69 million.
For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.
... More